Overview
At ADARx, we are committed to better outcomes for patients. We leverage our innovative RNA therapeutic approach with a goal of providing highly effective and convenient treatments addressing unmet needs across a broad range of diseases, including genetic, complement-mediated, cardiometabolic and central nervous system diseases.
Patients are at the center of everything we do, and we work with urgency knowing that we have the potential to improve the lives of patients.
Clinical Trials
Advancements in RNA medicines would not be possible without participation from patients in clinical trials. Learn more about our ongoing clinical trials below:
Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients
Recruiting Status: Recruiting
Age: 18 – 65 Years Old
A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study in Healthy Volunteers and a Phase 2a, Open-Label Study in Patients with Hereditary Angioedema to Evaluate the Safety, Tolerability, PK and PD of ADX-324.
Safety, Tolerability, PK and PD of ADX-038 in HV and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
Recruiting Status: Recruiting
Age: 18 – 65 Years Old
The first-in-human Phase 1/Phase 2a study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in both healthy participants (HP) and in patients with paroxysmal nocturnal hemoglobinuria (PNH).
Safety, Tolerability, PK and PD of ADX-850 in Participants with Hypertension
Recruiting Status: Recruiting
Age: 18 – 65 Years Old
The first-in-human Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ADX-850 in patients with hypertension.
